Exclusive Summary

• - Core composition patents have expired; oral generics are scarce globally, offering “first/early generic” opportunities outside markets with orphan/exclusive barriers.
• - ALS-focused positioning with ~200–300k prevalent patients worldwide and 40–60k incident cases annually indicates sustained demand for long-term, convenient therapy.
• - Evidence shows slowed ALSFRS-R decline in selected patients; multiple country guidelines list it as an option (not on WHO EML), and an oral tablet markedly improves access and adherence.
• - Injections are commoditized, while oral approvals are limited (mainly US/Japan brand ORS), leaving whitespace in many emerging markets for a differentiated solid oral.
• - With CN MA and ICH-CTD/BE/stability data, the product can support reliance registrations and cross-border licensing, and can be priced 40–70% below originator where no exclusivity applies.